PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations

Immune checkpoints are important targets for immunotherapies. However, knowledge on the epigenetic modification of immune checkpoint genes is sparse. In the present study, we investigated promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Röver, Lea Kristin, Gevensleben, Heidrun, Dietrich, Jörn, Bootz, Friedrich, Landsberg, Jennifer, Goltz, Diane, Dietrich, Dimo
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5835568/
https://ncbi.nlm.nih.gov/pubmed/29396294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.01.016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars